Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) has shared an announcement.
Cizzle Biotechnology Holdings PLC has released its Annual Report and Financial Statements for the year ending December 31, 2024. The report highlights the company’s progress in developing its proprietary cancer detection technology and its strategic collaborations and licensing agreements. This announcement underscores Cizzle’s ongoing commitment to advancing early cancer detection and its efforts to strengthen its market position through strategic partnerships.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics company specializing in the development of early cancer detection tests. The company has developed a non-invasive, cost-effective blood test based on the CIZ1B biomarker, which is associated with early-stage cancer, particularly lung cancer. Cizzle has entered into commercial royalty-bearing agreements to license its technology and collaborates with cancer care centers of excellence.
YTD Price Performance: 3.23%
Average Trading Volume: 680,979
Technical Sentiment Signal: Buy
Current Market Cap: £6.34M
For a thorough assessment of CIZ stock, go to TipRanks’ Stock Analysis page.